Laboratory medicine best practices : developing an evidence- based review and evaluation process. Final technical report 2007: Phase I. by Snyder, Susan R. et al.
Laboratory Medicine Best Practices:  
Developing an Evidence-Based  
Review and Evaluation Process
Final Technical Report 2007: Phase I
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
Acknowledgments
The following report represents the collective efforts of many people dedicated to improving the quality of 
laboratory medicine. The authors would like to recognize several people whose support, guidance, expertise, 
and commitment have made it possible to develop an evidence-based process for identifying best practices.
Many people at the Centers for Disease Control and Prevention (CDC) and the U.S. Department of Health and 
Human Services (HHS) have been committed to the development of this process. They include the exceptional 
project oversight and content contributions of Julie R. Taylor, PhD, and the content expertise and support  
of D. Joe Boone, PhD, Devery Howerton, PhD, Emily S. Reese, MPH, and CDC consultant  
Linda McKibben, MD, MPH.
We are extremely grateful to the Laboratory Medicine Best Practices Workgroup members for their time 
and dedication to this process. Their thoughtful consideration of each step in the process, coupled with their 
commitment to improving laboratory medicine, was fundamental in developing Phase I of this process. We 
extend our appreciation to Raj Behal, MD, MPH, Nancy Elder, MD, MSPH, John Fontanesi, PhD, Julie 
Gayken, MT (ASCP), Cyril (“Kim”) Hetsko, MD, FACP, Lee Hilborne, MD, MPH, Michael Laposata, MD, 
PhD, James Nichols, PhD, Mary Nix, MS, MT (ASCP), SBB, Stephen Raab, MD, Fatema Salam, MPH, and 
Ann Watt, MBA. We also appreciate the contributions of our two ex-officio members Sousan S. Altaie, PhD, 
and James A. Cometa. Expert guidance on laboratory services was provided by Diana Mass, MA, MT (ASCP), 
CLS (NCA), consultant to Battelle Memorial Institute.
Administrative support was provided by Alessandra Favoretto, Eileen Miles, Susan Pearce, and Lynne Jones. 
Editorial and graphic design assistance were provided by Denise Williams and Kate Mollenkamp. We also are 
grateful for the transcription services provided by Marie Murray.
Suggested Citation
Centers for Disease Control and Prevention. Laboratory Medicine Best Practices: Developing an Evidence-
Based Review and Evaluation Process. Final Technical Report 2007: Phase I. Atlanta: U.S. Department of 
Health and Human Services; 2008.
Disclaimer
Web site addresses of nonfederal organizations are provided solely as a service to our readers. Provision of an 
address does not constitute an endorsement by the Centers for Disease Control and Prevention (CDC) or the 
federal government, and none should be inferred. CDC is not responsible for the content of other organizations’ 
Web pages.
Laboratory Medicine Best Practices: 
Developing an Evidence-Based Review 
and Evaluation Process
Final Technical Report 2007: Phase I
Prepared for
Division of Laboratory Systems
National Center for Preparedness, Detection, and Control of Infectious Diseases 
Centers for Disease Control and Prevention
Atlanta, Georgia
Prepared by
Centers for Disease Control and Prevention
Susan R. Snyder, PhD, MBA
Pamela J. Thompson, MS, MT (ASCP)
Colleen S. Shaw, MPH
Battelle Memorial Institute
Laura A. Puzniak, PhD, MPH
Edward B. Liebow, PhD
Robert S. Black, MPH




U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
The findings and conclusions in this report are those of the author(s) and do not represent the 







Expert Workgroup Selection ..................................................................................................5
In-person Workgroup Meetings .............................................................................................6







Literature Search Strategy ...................................................................................................12
Inclusion/Exclusion Criteria ..................................................................................................12
Data Abstraction and Synthesis ...........................................................................................13






Feasibility of Implementation ................................................................................................17
Impact Assessment .............................................................................................................17
Strength of Evidence ...........................................................................................................18
Recommendations ..............................................................................................................18
Results And Recommendations ....................................................................................... 20 
Proof of Concept .........................................................................................................................20
Review and Evaluation Methods ................................................................................................21
Structure and Sustainability .......................................................................................................22
Next Steps ...................................................................................................................................24
References ......................................................................................................................25
Appendix A. Process to Identify Best Practices in Laboratory Medicine .........................26
Appendix B. Laboratory Medicine Best Practice Workgroup Roster ................................27
Appendix C. Selection Process for Study Inclusion and Review Results .........................29
Appendix D. Data Abstraction Form ................................................................................30
Appendix E. Evidence Summary Tables: Bar-Coding Identification Systems ...................34

Executive Summary
Clinical laboratory services play a vital role in the delivery of individual health care and 
public health in the United States. The U.S. Department of Health and Human Services’ 
(HHS) Centers for Medicare & Medicaid Services (CMS) certifies over 200,000 laboratories 
in the United States under the provisions of the Clinical Laboratory Improvement 
Amendments of 1988 (CLIA).1 These laboratories provide more than 1,000 laboratory tests 
for human conditions; about 500 of these tests are used daily.2 
The Centers for Disease Control and Prevention (CDC) is committed to organizing a national 
effort to promote the use of best practices in laboratory medicine. In response to the Institute 
of Medicine’s call to improve quality in medicine,3 CDC’s Division of Laboratory Systems 
(DLS) is supporting the development of a systematic, evidence-based process to identify best 
practices in laboratory medicine. 
This effort was undertaken in October 2006 when DLS convened the Laboratory Medicine 
Best Practices Workgroup, a multidisciplinary advisory panel including experts in laboratory 
and clinical medicine, health systems and policy research, performance measurement, and 
standard setting. The Workgroup was supported by a team from DLS and a contractor, 
Battelle Memorial Institute (Battelle). The goal of the effort is to develop a process 
for making best practice recommendations that will assist professional organizations, 
government agencies, laboratory professionals, clinicians, and others who provide, use, 
regulate, or pay for laboratory services. 
The process focuses on improving laboratory medicine by identifying and evaluating best 
practices that achieve the following:
•	 Enhance the quality of laboratory services and patient outcomes.
•	 Reduce redundancy and waste.
•	 Enable laboratories to define opportunities for quality improvement.
To date, the Laboratory Medicine Best Practices development process has two phases.
Phase I (October 2006 – September 2007) 
The key steps involved in Phase I of this project included the following:
•	 Establish key terms and definitions related to best practices in laboratory medicine.
•	 Develop inclusion and exclusion criteria for candidate laboratory medicine practices.
•	 Create a classification scheme for organizing candidate practices.
•	 Identify priority criteria and topic areas for candidate practices.
•	 Develop systematic review methods to comprehensively search the literature and 
other relevant information sources, screen references, abstract data, and summarize 
results. 
•	 Create an evaluation framework for making best practice recommendations on the 
basis of assessment of a practice’s potential impact (effect size and feasibility) and the 
strength of evidence.
•	 Conduct a proof of concept exercise to test the review methods and evaluation 
framework.
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•	 Assess results of the proof of concept and make necessary revisions to the process 
methods.
•	 Define strategic organizational and implementation constructs.
•	 Determine the next steps for Phase II.
Developing methods for identifying and evaluating candidate practices was challenging 
because of the limited availability of peer-reviewed, published, and accessible evidence 
related to laboratory medicine practices. As the Support Team and Workgroup progressed 
through the proof of concept exercise, the need to modify standard systematic review 
methods to address the state of evidence in the field of laboratory medicine became apparent. 
Members of the Workgroup agreed that considerably more evidence that is not accessible by 
conventional means might be available. 
To address the need to find and incorporate more evidence into the process, the Workgroup 
recommended that a systematic and transparent methodology be created to include 
unpublished evidence that is not readily accessible. This methodology includes an 
“investigational component” to review, in a systematic fashion, evidence from sources that 
are not traditionally considered in the evaluation of medical evidence of effectiveness. This 
component incorporates a process loop to refine the evidence base over time as additional 
data become available. 
Phase II (October 2007 – September 2008) 
In Phase II, the key components are to
•	 Refine and develop process review and evaluation methods.
•	 Develop the investigational component recommended in Phase I. 
•	 Develop a laboratory network for soliciting practices and evidence. 
•	 Pilot test the process.
•	 Evaluate alternative organizational structures for implementing and sustaining this 
process. 
Once Phase II is completed, the process will be more refined, and a new investigational 
component will be added to address the evidence gap in the literature. Efforts are under 
way to ensure that the Laboratory Medicine Best Practices recommendation process is 
sustainable and facilitates dissemination of best practices to relevant stakeholders. 
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Background
Laboratory medicine is an essential part of health care systems. More than 200,000 U.S. 
laboratories are certified by the Centers for Medicare & Medicaid Services (CMS) of the 
U.S. Department of Health and Human Services (HHS) under the provisions of the Clinical 
Laboratory Improvement Amendments of 1988 (CLIA).1 CLIA regulations set minimum 
quality standards for clinical laboratory testing. 
National initiatives that address all areas of health care should include laboratory practices. 
The Agency for Healthcare Research and Quality (AHRQ) has led national efforts to review 
and compile available information in its National Guidelines Clearinghouse and National 
Quality Measures Clearinghouse. AHRQ also is building a database of health service 
delivery innovations for its new initiative, the AHRQ Health Care Innovations Exchange. 
Laboratory medicine practices that satisfy AHRQ’s inclusion criteria may be included in 
these databases.4 The National Quality Forum (NQF) is conducting numerous projects to 
endorse consensus-based recommendations for health care-related performance measures 
and practices that include screening, diagnosing, and treating various chronic and infectious 
diseases, and patient safety practices.5
In laboratory medicine, efforts to develop guidelines, standards, policies, and best practice 
recommendations have typically been independent ventures that serve specific fields or 
professions. Professional organizations and industry associations, such as the College of 
American Pathologists (CAP), the Clinical and Laboratory Standards Institute (CLSI), and 
the Clinical Laboratory Management Association (CLMA), have developed approaches to 
recommending and disseminating quality practices. In some cases, government agencies 
and accrediting bodies have recognized these recommendations as meeting regulatory and 
accreditation requirements. 
A more global approach to evidence-based recommendations is needed because many 
processes affect quality in laboratory medicine. Errors can be introduced in selecting and 
ordering appropriate clinical tests, obtaining patient specimens, conducting tests, reporting 
results to clinicians, and interpreting laboratory results.6 
The following commonly encountered errors7 can reduce patient safety or otherwise 
contribute to adverse health outcomes for patients, and diminish health care quality and 
patient satisfaction: 
•	 Ordering the incorrect sequence of tests. 
•	 Incorrectly identifying the patient and specimens.
•	 Performing laboratory tests improperly.
•	 Interpreting results incorrectly.
•	 Communicating results inaccurately.
•	 Misinterpreting or failing to understand the clinical significance of test results. 
The potential consequences of these errors, virtually all of which can be reduced or 
prevented through changes in systems and processes, demonstrate the need for an evidence-
based model for recommending laboratory medicine practices. Reinforcing this need is the 
continual evolution of medical technology, the emergence of entirely new fields of testing 
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(e.g., pharmacogenomics), and the discovery of new applications for existing laboratory tests. 
A systematic approach is needed to identify laboratory practices that are effective in reducing 
error rates, improving patient outcomes, and increasing efficiency. 
Recognizing these opportunities for errors in the multifaceted process of clinical laboratory 
testing, CDC’s Division of Laboratory Systems (DLS) is leading a concerted national effort 
to apply an evidence-based approach to evaluating and recommending best practices in 
laboratory medicine, consistent with Institute of Medicine (IOM) recommendations.3,8 No 
single evidence-based model for recommending practices in laboratory medicine exists, 
although the number of laboratories operating in the United States and the volume of 
laboratory tests available certainly warrant such a model. Of more than 1,000 laboratory tests 
for human conditions, about 500 are used daily.2 These tests help health care practitioners 
and patients make decisions about disease prevention, assessment, diagnosis, treatment, and 
management and are key components in clinical decision making.9 
In evidence-based medicine, clinical anecdotes and expert opinion can be taken into 
consideration in evaluating the effectiveness of an intervention, service, or practice, but 
only in conjunction with a body of scientifically valid, peer-reviewed evidence.10 The term 
evidence-based medicine first appeared in the literature in 1990 and began to flourish in 
1993, with the publication of a 25-part series in JAMA titled The User’s Guide to Medical 
Literature.11 Evidence-based medicine applies criteria to interpreting and evaluating the 
validity of evidence and the value of clinical information before clinical decision making.6,12,13 
Laboratory medicine best practice recommendations should be supported by evidence-
based evaluations. Yet evidence demonstrating the effect of laboratory testing on health 
outcomes or even on intermediate clinical outcomes and process outcomes is extremely 
limited. Laboratory tests and associated practices are part of a more encompassing total 
testing process,14 and health outcomes are affected by a combination of multiple steps in this 
process. In addition, more basic evidence of effectiveness is missing for some well-accepted 
practices, standards, recommendations, and requirements because historical application is 
taken as ample support in lieu of well-designed studies.
As part of an initiative to improve quality in laboratory medicine, DLS convened a 
multidisciplinary 14-member Laboratory Medicine Best Practices Workgroup, which was 
charged with developing an evidence-based process to identify, evaluate, and recommend 
best practices in laboratory medicine. This process addresses how to make best practice 
recommendations that would provide guidance to professional organizations, government 
agencies, laboratory professionals, clinicians, and others who provide, use, regulate, or 
pay for laboratory services. The process is designed to improve laboratory medicine by 
identifying and evaluating best practices that
•	 Enhance the quality of laboratory services and patient outcomes.
•	 Reduce redundancy and waste.
•	 Enable laboratories to define opportunities for quality improvement.
Efforts are under way to ensure that the Laboratory Medicine Best Practices recommendation 
process is sustainable by building an infrastructure that is based on partnerships and 




This report describes DLS’ initial development of a systematic, evidence-based process for 
making best practice recommendations. A Support Team that included CDC and Battelle 
staff worked with the Laboratory Medicine Best Practices Workgroup to develop the overall 
approach, which involved the following steps:
1. Establish key terms and definitions related to best practices and laboratory medicine.
2. Develop inclusion/exclusion criteria for candidate laboratory medicine practices.
3. Create a classification scheme for organizing candidate practices.
4. Identify priority criteria and topic areas for candidate practices.
5. Develop systematic review methods to comprehensively search the literature and other 
relevant information sources, screen references, abstract data, and summarize results. 
6. Create an evaluation framework for making best 
practice recommendations based on assessment 
of a practice’s potential impact (effect size and 
feasibility) and the strength of evidence.
7. Conduct proof of concept to test the review 
methods. 
8. Assess results of the proof of concept and make 
necessary revisions.
9. Define strategic structural and implementation 
constructs.
10. Determine the next steps to be included in 
Phase II.
The following schematic depicts the team’s approach to developing this process.  
See Appendix A for a more detailed illustration.
Expert Workgroup Selection
To be effective, the Laboratory Medicine Best Practices process needs to be developed 
by stakeholders representing a broad array of scientific, practitioner, payer, and patient 
communities. Thus, CDC convened a multidisciplinary panel of experts to create this process 
(see Appendix B). Members of the Laboratory Medicine Best Practices Workgroup were 
recruited and selected on the basis of their experience, interest, and expertise in one or more 
of the following categories:
•	 Performance measurement
•	 Health systems
























Development Process At a Glance
Oct 2006 CDC DLS launches effort to recommend 
best practices 
Dec 2006 Workgroup kickoff phone conference
Jan 2007 First Workgroup In-Person Meeting
Feb–Mar 2007 Initial development of review methods and 
evaluation framework
Apr–May 2007 Review of literature/proof of concept for 
review methods
Jun 2007 Second Workgroup In-Person Meeting
Jul–Nov 2007 Report developed and next steps 
determined 
Dec 2007 Final Report
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Workgroup members were asked to participate in two face-to-face 2-day meetings and 
multiple conference calls. They also provided e-mail feedback in response to specific queries 
and document drafts. The 14-member Workgroup was supported by staff from DLS and 
Battelle (Support Team). 
In-Person Workgroup Meetings
The goal of the first Workgroup meeting (January 2007) was to gain input on the conceptual 
approach for the methodology that members would use to develop the process. Workgroup 
members discussed and offered recommendations on working definitions, inclusion and 
exclusion criteria, classification systems, topic priorities, and review and evaluation methods. 
The Workgroup had the opportunity to comment on the conceptual approach during the 
meeting and to answer directed questions in a follow-up inquiry. 
After the first Workgroup meeting, two subgroups were created—one focusing on developing 
a methodology for evidence reviews (Review Methods Subgroup) and the other focusing on 
developing an evaluation framework (Evaluation Subgroup). These subgroups worked via e-
mail and conference calls. 
The objectives of the second Workgroup meeting (June 2007) were to review work completed 
on the methodology for evidence reviews and the evaluation framework, and to make recom-
mendations for further development. Meeting discussion included 1) review and refinement 
of methods for identifying and reviewing candidate best practices, 2) general criteria for 
evaluating and recommending best practices, and 3) next steps for pilot-testing the process 
and disseminating recommendations. 
The Workgroup used a series of proof of concept exercises to apply proposed methods 
to reviewing and evaluating candidate practices in the topic area of patient/specimen 
identification, a priority area identified by the Workgroup. Members also addressed specific 
conceptual and operational features for the process, especially as these features related to an 
organizational structure. 
Workgroup members had the opportunity to comment on the meeting summaries and to pro-
vide an overall evaluation of the process, the in-person sessions, and the facilitation of the 
sessions.
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Laboratory Medicine Best  
Practices Definitions
• Best Practices are practices integral to the provision 
of laboratory medicine services that increase the 
probability of beneficial patient outcomes, as 
demonstrated by scientific evidence (or in the 
absence of such direct evidence, consensus expert 
opinion) that the practice in question supports the 
Institute of Medicine’s (IOM) quality domains.
• Laboratory Medicine encompasses testing services 
and associated practices for the assessment, 
diagnosis, treatment, management, or prevention of 
health-related conditions.
• Laboratory Tests include any test or examination 
of materials derived from the human body for 
the purpose of making patient care decisions and 
improving public health.
• Practices are protocols, procedures, policies, 
techniques, processes, systems, standards, incentives, 
activities, and interventions that are used to provide 
health care to patients.
Process Development Constructs
Definitions
Working definitions for best practices and laboratory medicine were reviewed and revised 
by the Workgroup during the kickoff call and at the first in-person meeting. The Workgroup 
emphasized the need for simple and comprehensible definitions.
Workgroup members expressed concerns about using the 
term best to describe practices, and suggested alternatives 
such as quality, effective, and preferred. The term quality 
was rejected because laboratory practices may not match 
the domains of quality assessment and management as 
these are understood in the broader health care system. 
Effective was excluded out of concern that it implied a 
linkage that might not be available between the practice and 
some favorable health outcome, and because it might not 
capture other domains. Preferred was excluded because it 
raised questions about who prefers the practice and implies 
endorsement of one practice or policy over another. In the 
end, members of the Workgroup decided to use the term 
best practices because it is commonly used and widely 
understood in the field. 
The Workgroup members agreed that laboratory medicine 
should be defined in an inclusive manner and opted to 
categorize laboratory medicine testing services into 
“assessment, diagnosis, treatment, management, or 
prevention of health-related conditions” instead of trying to 
list individual types of testing. Moreover, by adding “any 
test or examination of materials derived from the human body,” the definition for laboratory 
medicine includes the realm of testing and also focuses on human laboratory tests in contrast 























Workgroup members were asked to 
develop the minimum criteria for 
a practice to be considered for the 
Laboratory Medicine Best Practices 
process. These parameters represent 
the basic criteria for a practice to be 
considered for further and more detailed 
evaluation. Key components of the 
inclusion criteria are that the practice is 
current, replicable, population-based, 
has potential to improve outcomes, 
and is supported by direct evidence of 
effectiveness or by expert opinion.
The Workgroup discussed the limited 
quantity and quality of scientific evidence 
available for laboratory medicine 
practices and the difficulty creating 
a hierarchical model for rating these 
practices. 
Members agreed that the “opinions of respected authorities based on clinical evidence, 
descriptive studies of clinical reports, or reports of expert committees” would be an 
acceptable minimum level of evidence for a candidate practice in lieu of some level of 
direct evidence. However, the Workgroup members expressed a preference for a systematic, 
multidisciplinary evaluation process. 
Classification Scheme
 
The Workgroup reviewed the following classification schemes:
•	 Clinical conditions (e.g., diabetes, heart disease, infectious disease).
•	 Health care settings (e.g., hospital, physician office, point-of-care, nursing home).
•	 Laboratory total testing process (pre-analytical, analytical, post-analytical).
Minimum Inclusion Criteria
•	 The practice is in current use and available for immediate application.
•	 The practice can be reproduced in other comparable settings.
•	 The practice impacts a defined group of patients. 







•	 The practice identifies a potential improvement in an outcome that can 








•	 The practice is supported by some evidence of effectiveness or by expert 










































•	 National health care quality priorities (e.g., NQF, IOM, AHRQ).
•	 Functional model (based on the continuum of care for analytical individual patient 
testing within a single disease process).
•	 IOM continuum of care across the life span based on the developmental periods of a 
patient’s life (i.e., newborn, adolescent, adult).
•	 Hybrid model based on a report issued by NQF,15 which combines the laboratory total 
testing process and national health care quality priorities based on an evidence-based 
review of guidelines and performance measures associated with laboratory tests.
The Workgroup members reached a general consensus to use an expanded version of the total 
testing spectrum of laboratory medicine similar to the hybrid model in the NQF report. They 
recommended focusing on the pre-analytic and post-analytic components of the total testing 
process, with particular attention to communication between the laboratory and clinicians 
to ensure that test results are appropriately interpreted. This focus should be balanced 
with a global perspective on the testing process through the health care continuum, which 
encompasses all areas of laboratory medicine. The Workgroup also acknowledged that such a 
hybrid model would be more useful than a linear model. 
Priorities
The Workgroup considered several methodological models for identifying priority topic 
areas for evidence-based systematic reviews and recommendations. These included The 
Community Guide,16 the National Academy of Clinical Biochemistry’s (NACB) Laboratory 
Medicine Practice Guidelines (LMPG),17 the U.S. Preventive Services Task Force’s 
(USPSTF) Guide to Clinical Preventive Services,18 and the Oxford Centre for Evidence-
Based Medicine’s Levels of Evidence.19 When the criteria for setting priorities used in these 
models are compared, considerable overlap becomes apparent. Although the terminology 
used differs among the models, they have the following constructs in common:
•	 Burden of the problem
•	 Preventability




The Workgroup completed an exercise intended to identify topic areas for development of 
best practices. From this list, lack of accurate patient identification and labeling of specimens 
was chosen as the topic area for completing the Phase I proof of concept, a preliminary test 
of this process. This topic area offered some evidence of the effectiveness of practices and 
many challenges that are not unique to this topic area (e.g., lack of standardized definitions 






















Workgroup Priority Topics (January 2007)
•	Identification of organizational structures that promote good management. 
•	Lack of accurate patient identification and labeling of specimens. 
•	Accurate incorporation of results into patient treatment plan.
•	Communication between laboratory and ordering physician about which test to select and 
clinical significance of results. 
•	Electronic display of laboratory data (i.e., how it will be displayed). 
•	Accessibility of laboratory services. 
•	Post-analytic reporting of results. 
•	Read back of critical value test results and test ordering. 
•	Challenge of integrating laboratory information with other clinical data to optimize patient 
safety. 
•	Identification of practices that have high probability for improving quality care. 
•	Finding the best way to handle information transmissions between laboratory and offices. 
•	Reporting results to the patient. 
•	Appropriate blood product selection. 
•	Promoting the value of laboratories (to the general public and clinicians). 
•	Standardized policies for training and continual training on how to collect samples. 
•	Setting up a Computerized Physician Order Entry system for ordering laboratory services. 
•	Ensuring that laboratory goals (National Quality Agenda) are met consistent with national 
health care priorities. 
•	Ensuring an appropriate and trained workforce. 
•	Ensuring monitoring of follow up of patients on the basis of laboratory results. 
•	Introduction and dissemination of new techniques to laboratories and physicians. 
•	Communication to patient before laboratory testing to ensure patient is aware of the process. 
Review Methods
To develop the review methods needed to recommend best practices, the CDC Review 
Team completed a comprehensive review of methodology consistent with an evidence-based 
evaluation and recommendation process. With guidance from the Review Methods Subgroup, 
methods were developed, including an analytic framework, a literature search strategy, a 
data abstraction form, and an evidence summary table for each practice. These methods were 
then applied to the topic of patient/specimen identification. Workgroup members reviewed 
























An analytic framework (see Figure 1) shows how quality improvements in laboratory medi-
cine can lead to positive outcomes. In the systematic review and assessment of evidence, an 
analytic framework is essential because it helps reviewers specify the issue/problem, deter-
mine how it can be prevented or performance improved, and identify interventions and prac-
tices that may ultimately improve health outcomes. The analytic framework also explicitly 
encompasses the identification of potential harms associated with the practice or intervention. 
An analytic framework defines and clarifies the scope of a topic area (or subtopics within 
a topic area) so that it can be consistently applied by workgroups/teams. Putting these 
concepts and their relationships into a simple framework creates a structured approach to 
implementing review methods that will be adequately transparent and understandable to 
external reviewers. An application of the analytic framework for the quality issue of patient/
specimen identification errors is illustrated in Figure 2.
Figure 1: Analytic Framework for Laboratory Medicine Topic
Figure 2: Patient/Specimen Identification Topic Analytic Framework
Preventability/
Improvement
• ~100% preventable 
• Error rate range: <1% to 
>50%
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The CDC Review Team developed a 
comprehensive literature search strategy to 
systematically review the literature and identify 
candidate best practices. Team members developed 
applicable search terms for the review topic of 
patient/specimen identification. The search strategy 
was limited to English language literature with 
publication dates no earlier than 1996. 
Multiple databases were used to search the literature, including the following:
•	 PubMed 
•	 Cochrane databases
•	 Professional guidelines electronic databases (e.g., CLSI, ISO, NACB)
The team members manually searched journals, reports, conference proceedings, guidelines, 
technical reports of relevance to the review topic, and reference lists of relevant publications. 
The search strategy also included consulting with Review Methods Subgroup members to 
identify further research and information relevant to the review. 
Inclusion/Exclusion Criteria
Two reviewers independently screened titles and abstracts 
of identified literature using the initial topic-specific 
selection criteria and the minimum criteria for candidate 
practices developed by the Workgroup. These references 
were compiled to generate a table of pre-data abstraction 
references, which were grouped by practice area. 
Full text copies of 58 relevant references were screened 
and reviewed independently by at least two reviewers 
using standard exclusion criteria developed by the CDC 
Review Team. Applying the standard exclusion criteria, 
17 references were selected for full data abstraction. The 
selection process and review results are summarized in a 
flow diagram in Appendix C.
Initial Search Terms for Patient/Specimen 
ID Candidate Practices
•	Laboratory identification (ID) errors.
•	ID errors AND patient AND specimen. 
•	Laboratories AND ID systems AND specimen 
misidentification. 
•	Specimen labeling errors. 
•	 Information systems AND hospitals AND reduce ID errors.
Selection Criteria for Patient/
Specimen ID Review Topic
The title or abstract of the article addresses
•	ID errors in laboratory medicine/approaches for 
reducing ID errors.
•	Error-detection methods for specimen/ID errors or 
frequency of errors. 
•	Patient/specimen ID errors. 
•	Quality improvement programs/patient safety 
initiatives to reduce specimen/ID errors. 
•	Technology to improve processes in areas of 
laboratory medicine. 
•	Literature that addresses specific case studies, 
guidelines, or conceptual frameworks for reducing 
ID errors.
Standard Exclusion Criteria 
•	Practice not sufficiently described. 
•	Article/study did not assess practice. 
•	Article/study is commentary or opinion article.
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Data Abstraction and Synthesis 
A Data Abstraction Form was developed to consistently identify and then synthesize key 
components from the references (see Appendix D). The fields selected for abstraction were 
based on the information needed to summarize and evaluate the evidence. The abstraction 
form was primarily based on criteria established by The Community Guide,16 the National 
Academy of Clinical Biochemistry,17 and the U.S. Preventive Services Task Force.18 
Components included in the abstraction form were
•	Reference information
•	Practice description and characteristics
•	Implementation context
•	Study description (e.g., design, sample size 
and characteristics, dates/time period, setting, 
comparators)
•	Outcome measure types and descriptions
•	Effect size
•	Statistical analysis




•	Benefits (other than outcome measures)
•	Potential harms (other than outcome measures)
Most studies involving pre- and post-analytical laboratory medicine are likely to be practice-
oriented research using nonrandomized, quasi-experimental, or observational designs. 
Compared with randomized controlled studies, these designs are considered to have greater 
limitations with respect to internal validity. By the same token, findings of observational 
and quasi-experimental study designs may be more broadly generalizable (i.e., have 
greater external validity) than are the findings of narrowly designed randomized studies.20 
Consequently, some assessment of the internal and external validity of studies included in the 
review was deemed appropriate to characterize the quality of the studies. Summary ratings 
of internal validity and external validity were developed on the basis of study characteristics 
reported in each article reviewed.
For the patient/specimen identification topic proof of concept, 17 references were selected for 
full review. Each reference was abstracted by at least two independent members of the CDC 
Review Team using the Data Abstraction Form, and the information was summarized using 
an evidence summary table for each practice. These were case studies or longitudinal studies. 
Three of the references included more than one practice and were used in evaluating multiple 
practices. 
Internal and External Validity 
Internal Validity Rating: Based on how many of the 
following abstraction criteria were met: 
•	Outcome variable(s) clearly specified.
•	Study sample groups comparable  
(e.g., pre- and post-intervention).
•	Measurement methods comparable.
•	Confounding factors addressed.
External Validity Rating: Based on a combination of the 
internal validity rating and how many of the following 
abstraction criteria were met:
•	Finding(s) can be transferred to locations beyond those 
specifically included in the study.
•	Identified practice can be applied to additional settings. 
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The references identified the following eight candidate best practices for reducing patient/
specimen identification errors: 
•	 Bar-coding identification systems





•	 Zero tolerance policy
•	 Wristband monitoring
Evidence Summary Tables
The review team faced several expected challenges, including limited quality and quantity 
of evidence and the lack of clearly defined data elements that could be used to evaluate the 
candidate practices. As a solution, the review team created the following three categories of 
review information to account for the limited evidence on practice effectiveness:
•	 Evidence includes articles that reported some quantified information related to the 
effect of a practice (i.e., effect size). 
•	 Feasibility Information Only includes articles that reported information specific to 
practice implementation and/or cost. 
•	 Related Information includes articles that were relevant to the practice but did not 
contain any data elements that could be consistently evaluated. However, these 
articles might offer contextual or other supporting information related to the practice. 
An evidence summary table format was developed that included characteristics for each 









•	 Practice link to results
•	 Feasibility
•	 Cost
•	 Benefits and harms 
Evidence summary tables were completed for each of the eight patient/specimen 
identification practices. (See Appendix E for a sample completed evidence summary table 
related to Bar-Coding identification systems.)
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Evaluation Framework 
Two primary sources were used to develop the evaluation methodology for recommending 
best practices in laboratory medicine: performance measures and evidence-based guidelines. 
The latter were considered most relevant given their relative similarity and applicability to 
practices. Multiple organizations such as The Community Guide,16 National Association 
of Clinical Biochemistery (NACB),17 Oxford Centre for Evidence-based Medicine,19 U.S. 
Preventive Services Task Force (USPSTF),18 and others21 have specified methodologies 
for evaluating and recommending practices, interventions, and guidelines. During the first 
in-person Workgroup meeting, an overview of these existing models was provided to the 
Workgroup. Although none of these methods was tailored to laboratory medicine, they 
provided an array of constructs that facilitated Workgroup discussion about what might work 
for laboratory medicine. 
Evaluation Subgroup
To continue development of an evaluation framework, the Evaluation Subgroup was formed 
within the Workgroup. The subgroup developed assumptions, criteria, and ratings for 
evaluating candidate practices and recommending best practices for laboratory medicine 
by searching the literature and consulting with content experts to develop an evaluation 
framework tailored to laboratory medicine.
Assumptions
Three key assumptions guided development of an evaluation framework for this process. 
•	 Laboratory medicine interventions or practices are not likely to have been 
studied in randomized controlled trials. To date, trials in which individual patients 
or individual sites are assigned randomly to intervention or control groups for a 
laboratory procedure or practice evaluation are not typically available, primarily 
because of practical difficulties associated with conducting such trials.
•	 The evidence available to assess a candidate practice’s effectiveness is most likely 
to come from observational studies. Two kinds of study designs are most likely 
to be available: 1) observational study designs, such as case-control studies, cohort 
studies, or hybrid case-cohort studies that examine the potential impact of the practice 
on patient outcomes, and 2) operations research/management science studies (e.g., 
case studies), including those conducted in a quality management framework, such 
as Failure Mode and Effects Analysis (FMEA), Lean,22 or total quality management 
(TQM). These management approaches are likely to focus on intermediate or process 
outcomes that can be linked by a chain of inference to patient outcomes.
•	 Evidence for effectiveness of a specific practice might be limited. The basis for 
evaluating the practice will be a structured, descriptive analysis or a systematic review 
of the available evidence combined with consensus expert opinion, the specific nature 























Candidate practices for the evaluation framework are identified by using review methods 
(such as those previously described) that characterize evidence of a practice’s effectiveness. 
For a practice to be considered a candidate, it must satisfy the minimum inclusion criteria 
(specified in the Inclusion/Exclusion Criteria section of this report), and there must be some 
indication that the practice has the potential to improve outcomes likely to affect the quality 
of patient care and health outcomes. 
The Workgroup recommended the following three evaluation criteria for rating the body of 
evidence for an individual practice or intervention to be considered a best practice: 
1) Effect size (i.e., the magnitude of change in an outcome measure attributable to the 
practice). 
2) Feasibility of implementation. 
3) Strength of evidence (i.e., the degree of confidence in the evidence/judgments). 
General descriptions of the practice evaluation criteria and their corresponding rating and 
recommendation methods are provided in the next sections of this report. These descriptions 
constitute the first stage of developing the Laboratory Medicine Best Practices evaluation 
framework. The specific strategies for determining the overall ratings for each of the three 
criteria, and for rating their respective individual characteristics and how they are combined 
to determine the overall rating, were not fully developed at the end of Phase I. 
In Phase II, more detailed specifications for the evaluation criteria and rating methods, 
required for completing the development of a transparent and consistent process for making 
recommendations, will be addressed. In a proof of concept exercise, Workgroup members 
applied the evaluation framework to assess the practice of using Bar-Coding systems for 
patient/specimen identification to refine their recommendations for the Laboratory Medicine 
Best Practices evaluation methods. 
Effect Size 
Effect size is determined by measuring a practice’s 
results in terms of outcomes that are likely to affect 
the quality of patient care and/or health outcomes. 
Quantifying the effect size can be difficult because 
of sparse evidence and often heterogeneous data. 
Therefore, the Evaluation Subgroup developed a 
categorical rating for assessing effect size using four 
levels: substantial, moderate, minimal/none, and 
adverse. 
These rating levels are not intended to correspond 
to uniformly specified values, but instead will be 
determined by the practice-relevant context. The first 
three levels refer to a desirable effect. Effect size 
assessment involves evaluating practice outcome 
measures, their size, importance, and quality. 
Effect Size Assessment
Effects (outcome variables) are clearly defined in terms 
of at least one of the following:
•	Clinical outcomes.
•	Operational/process outcomes (e.g., error rates).
•	Economic (e.g., cost of test/procedure, treatment, 
associated outcomes).
Effects (outcomes) are consistently measured over time
•	Effect size is reported.
•	Statistical analysis (e.g., p-value) is reported. 
Effect size is qualitatively expressed in categorical 




Feasibility of implementation involves assessment of
•	Costs of intervention (monetary, non-monetary 
quantitative information).
• Applicability and sustainability features.
•	Barriers to implementation. 
•	Benefits (in addition to outcomes). 
•	Potential harms (in addition to outcomes). 
Ease and feasibility of implementation can be 
assigned to a categorical scale (e.g., high, medium, 
low) based on information reported and ratings 
related to the characteristics above.
Feasibility of Implementation
Evaluating the feasibility of implementing a practice 
encompasses an assessment of its availability for 
immediate application, its applicability for multiple types 
of patients and settings, and its sustainability. Each of 
these characteristics is given a rating of high, medium, or 
low. In addition, barriers to implementation and benefits 
and harms of implementing the practice are characterized. 
On the basis of the minimum inclusion/exclusion criteria, 
if the practice is not in current use or immediately 
available for application, it is excluded from further 
analysis. An overall feasibility rating of high, medium, or 
low is developed for the practice.
Impact Assessment
After a practice’s ratings for effect size and feasibility of implementation are established, 
recommendations may be developed in a two-stage process: 1) assessing impact and 2) 
assessing the strength of evidence. In the impact assessment, results from the evaluation 
ratings for effect size and feasibility of implementation for a candidate practice are combined 
into a single impact rating. Impact assessment ratings can be positive, neutral, or negative. 
The following grid shows the impact assessment ratings associated with each combination of 
ratings for size of effect and feasibility. 
Best Practices in Laboratory Medicine
Impact Assessment Rating:




Substantial Positive Positive Neutral
Moderate Positive Positive Neutral
Minimal/None Neutral Neutral Negative
Adverse effect Negative Negative Negative
•	 A positive impact rating signifies that the practice or procedure will likely do more 
good than harm and is demonstrably (or shows promise of being) implementable and 
sustainable. 
•	 The neutral impact rating signifies that there are important trade-offs between the 
effect size, benefits/harms, and feasibility, or it is not clear whether the practice or 
procedure does more good than harm. Thus, its feasibility rating is not sufficient to 
offset its lack of effect size. 
•	 The negative impact signifies that the practice or procedure does not clearly do more 
good than harm and that it would not be considered a candidate for best practice 
recommendation. A negative impact rating also could signify that even though the 




The strength of evidence for a practice’s body of evidence is evaluated in the second stage of 
developing recommendations. The following criteria are examples of the various criteria that 
should be evaluated to determine the strength of evidence:
•	 The number of studies involving the same or similar procedure/practice.
•	 The internal and external validity of these studies.
•	 The aggregate sample size of multiple studies.
•	 The comparability of study sample groups among multiple studies.
•	 The comparability of measurement methods among multiple studies.
•	 The assessment of confounding factors.
•	 The consistency of findings reported among multiple studies. 
Randomized control trials, cohort studies, and case-control studies are not the evidence norm 
for laboratory medicine. Therefore, the evaluation must be based on a less definitive set of 
categorical criteria. The Workgroup agreed on the following four categories of evidence: 
•	 A strong designation would be for well-designed, multisite operations case studies or 
other more rigorous study designs that report effect size in quantitative terms and use 
an appropriate statistical analysis.
•	 A moderate designation would be given to descriptive evaluation studies and case 
reports with consistent results. 
•	 A suggestive designation would be given for qualitative or weak quantitative evidence 
(i.e., opinions of respected authorities consistent with supported models, on the 
basis of clinical experience, descriptive studies and case reports, or reports of expert 
committees).
•	 An insufficient designation would be given when there is no evidence-based support 
for recommendation (i.e., expert opinion only, with no specific case study data).
Recommendations
Recommendations are formulated in accordance with the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) Working Group findings23 to reflect the 
extent to which one can be confident that following the recommendations will do more good 
than harm. 
The Workgroup agreed on the following four classifications for recommendations:
•	 A practice receiving a rating of strongly recommend should be implemented in 
appropriate care settings. 
•	 A practice with a rating of recommend should be implemented, taking into account case 
study or narrative data concerning the sensitivity of outcomes to variations in implemen-
tation and/or care settings. 
•	 A practice with a rating of no recommendation for or against has a potentially favorable 
effect on health care outcomes and/or error reduction, but is not sufficiently supported by 
evidence to indicate that it should be implemented in appropriate care settings. Additional 
studies may be warranted to strengthen the relevant evidence base for this practice.
•	 A practice with a rating of recommend against should not be implemented because 
available evidence indicates it is not likely to result in more good than harm. 
Additional studies are not warranted to strengthen the relevant evidence base. 

The following grid shows how ratings for the impact assessment and strength of evidence are 
both considered to determine the recommendation rating.
Best Practices in Laboratory Medicine
Recommendation Rating:




Strength of Evidence Rating
















Negative Recommend against Recommend against Recommend against Recommend against
Nontraditional Evidence
The Workgroup also discussed criteria needed to evaluate “nontraditional” evidence and 
ways that this type of information could be integrated into the evaluation framework. The 
process should encompass consensus expert opinion, unpublished institutional assessments 
of proposed practices, and a targeted outreach or investigational component to collect 
evidence concerning practice effectiveness. This outreach component might encompass 
such mechanisms as calls for practices issued through professional societies, identification 
of leaders in a particular practice, or development of practice evaluation networks by using 
common protocols to collect evidence concerning the effectiveness of practices that meet a 
minimum threshold of study quality. Members of the Workgroup recommended that specific 
a priori criteria for evaluating evidence collected through such mechanisms should be set so 
that an expert panel can review the data using unbiased, systematic methods. 
Economic Evidence
The Workgroup discussed the use of economic evaluation evidence such as cost-effectiveness 
and cost-benefit studies in the evaluation framework. In most of the existing frameworks for 
making recommendations (e.g., Guide to Clinical Preventive Services and the Community 
Guide), no explicit criteria are given to address economic evidence. If economic evaluation 
evidence is available, it is generally addressed in summarizing recommendations and 
evidence. 
Workgroup members concluded that similar to the other models, economic evidence should 
be a consideration but not an explicit evaluation criterion. Members recognized that cost-
related information is generally highly valued by policy and decision makers, and such 
information is often the primary driver behind decisions to adopt practices. Therefore, 




For purposes of evaluating the proposed review methods and recommending changes, the 
Workgroup completed a proof of concept exercise during the second in-person meeting. 
Members assessed this application of the proposed review methods and evaluation framework 
to eight candidate practices on the topic of patient/specimen identification. 
Although the CDC Review Team attempted to provide the Workgroup with the largest 
possible number of studies and practices to consider in this exercise, some of the studies did 
not include adequate information on the practice or its effects. During the proof of concept 
exercise, the Workgroup applied basic relevance criteria to determine the appropriateness of 
including the study/practice in subsequent steps of the evaluation. 
The Workgroup discussed the various patient/specimen identification practices and 
determined which candidate practices should continue on to the evaluation framework. 
They made this decision on the basis of their opinion of how the available evidence for each 
practice met the following criteria:
•	Relevance to topic
•	Adequate specification
•	Consistent definition (if multiple studies)
•	Relevance of outcome measure for assessing practice effectiveness
•	Relevance of reported results for assessing practice effectiveness
The Workgroup advised moving the majority of the evidence articles and practices forward 
through the evaluation framework (excluding only two of the eight practice areas: marketing 
campaign and zero tolerance policy because of insufficient information for evaluation).
In completing the proof of concept, the Workgroup encountered several challenges. For 
instance, multiple practices and systems can be simultaneously involved and/or implemented, 
and measurement approaches and definitions vary greatly, making the actual primary 
outcome measure of identification error rates uncertain (e.g., ranging from 1% with self-
reporting to 63% with direct observation).24 In addition, no standardized data are available to 
measure identification errors or to determine their effects on patient care or health outcomes. 






















The Workgroup applied the proposed evaluation framework to the practice selected for 
evaluation: bar-coding identification systems. The Workgroup provided the following overall 
ratings:
•	 Feasibility of implementation: medium 
•	 Effect size: moderate
•	 Overall impact rating: positive 
The Workgroup did not provide a definitive rating of the strength of evidence for bar-coding 
identification systems. Specific issues in applying the process—how to weight information 
from different types of studies, how to account for nontraditional evidence in the framework, 
and how to place clinical relevance into the recommendation—were discussed at length. 
Although the Workgroup began applying the evaluation framework to this practice, the 
exercise did not include completing the process to the point of making a recommendation. 
The Workgroup’s evaluation framework proof of concept exercise highlighted the need to 
develop detailed specifications that can be consistently applied by expert panels to assess 
the relevant practice evidence characteristics that make up the three overall criteria ratings 
(feasibility of implementation, effect size, and strength of evidence). Clearly specified criteria 
and rating methods are required to achieve the goal of a Laboratory Medicine Best Practices 
recommendation process that is evidence-based and transparent.
Review and Evaluation Methods 
As the Workgroup progressed through the proof of 
concept exercise, it became increasingly apparent that the 
lack of peer-reviewed, published, and accessible evidence 
for laboratory medicine practices required a new and 
innovative approach. Members realized that although 
the Laboratory Medicine Best Practices process needs 
an evidence base, current standard systematic review 
methods and evidence-based recommendation models 
would have to be modified to take this lack of accessible 
information into account. The collective sense of the 
Workgroup was that considerably more evidence might be 
available that is not accessible by conventional means. 
To address the need to find and incorporate more evidence into the process, the Workgroup 
recommended that an investigational component be added to the process to systematically 
review evidence from “nontraditional sources.” The innovative features of this modified process 
are a systematic approach to incorporating evidence from sources other than peer-reviewed 
publications, and a process loop to refine the evidence base over time as evidence evolves. 
The Workgroup’s recommendation is not to wait for the evidence to catch up. Instead, they 
suggested that a process be developed to address gaps in the literature that can be filled by 
practitioners and expert groups with knowledge of institutional practices and unpublished 
studies. This nontraditional evidence can be gathered through focused and targeted outreach 
(e.g., identification of practice leaders, experts, and centers as well as calls for practices). 
This process is depicted in Figure 3.
Laboratory Medicine Best Practices 
Workgroup Methods Recommendations 
•	Address and incorporate nontraditional evidence 
that is not readily accessible for filling evidence 
gaps.
•	Create an investigational component and process 
loop for review methods.
•	Use focused and targeted outreach to access and 
develop evidence of practice effectiveness.
•	Set evidence criteria (including nontraditional 
evidence) a priori.
•	Revisit candidate topics with advisory group.
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Figure 3: Proposed Process for Identifying Best Practices in Laboratory Medicine 
Structure and Sustainability
At their June 2007 in-person meeting, Workgroup members addressed a series of conceptual 
and operational questions regarding implementation and sustainability of the Laboratory 
Medicine Best Practices recommendation process. The Workgroup members were provided 
an opportunity to provide individual, written feedback concerning many of these constructs 
in a follow-up inquiry after the June meeting. 
Before these sessions, three presentations were made to provide background information to 
the Workgroup, along with opportunities for discussion on related methods and processes. 
The first presentation was by Raj Behal, MD, MPH, and was based on his work for the NQF 
that summarized evidence and introduced a framework for laboratory medicine performance 
measures. Two other presentations provided overviews of evidence-based recommendation 
processes; these presentations were given by David Hopkins, MD, MPH, of The Community 










































































































The Workgroup provided recommendations 
on conceptual and operational structures and 
definitive next steps during the in-person 
meeting and by follow-up inquiry after the 
meeting. In the judgment of the Workgroup, 
CDC should retain control and direction of 
the process for developing best practices 
recommendations and is the appropriate 
organizational home for a data repository 
that might be developed as a result of the 
process. Workgroup members agreed that the 
data should be openly accessible and in an 
electronic, secure repository that protects the 
integrity of the work. 
The Workgroup agreed that multiple organizations should be stakeholders in the Laboratory 
Medicine Best Practices process and have a vested interest in its success. These organizations 
include pathology groups, accrediting organizations, hospitals, physicians, other health care 
providers, payers, and patients. To engage stakeholders and maintain interest in the process, 
the Workgroup recommended a multi-tiered approach that includes calls for practices, 
Listserv announcements, a Web site, and newsletters. 
Establishing an official publication to disseminate and document Laboratory Medicine 
Best Practices process methods and recommendations also was recommended to provide 
interested parties with a consistent method to obtain up-to-date information. The Workgroup 
identified specific organizations that would have an interest, including the National Academy 
of Clinical Biochemistry (NACB), American Society for Clinical Pathology (ASCP), College 
of American Pathologists (CAP), Clinical Laboratory Standards Institute (CLSI), American 
Association for Clinical Chemistry (AACC), Clinical Laboratory Management Association 
(CLMA), International Federation of Clinical Chemistry (IFCC) – Evidence-Based 
Laboratory Medicine Committee, National Quality Forum (NQF), the Joint Commission, and 
patient advocacy groups. 
The Workgroup recommended an overall coordinating/governing body to spearhead the 
continuing effort to develop the best practices process with expert panels for each topic 
area. They recommended that the effort be federally funded to ensure that its focus remains 
on a broad public health agenda. The Workgroup considered several barriers to successful 
implementation, including limited resources, competition, and varying interests. 
The Workgroup considered existing structural models in developing recommendations for 
an organizational structure and by-laws. Various existing organizational models and their 
structural components and similarities were discussed. The Workgroup identified issues that 
could be relevant to the proposed methodology for the process of identifying best practices. 
They recommended that a single advisory committee or task force be used for implementing 
the Laboratory Medicine Best Practices recommendation process. If an appropriate 
committee or task force does not already exist, one with open nominations and term limits 
should be established. 
Laboratory Medicine Best Practices 
Workgroup Operational Recommendations 
•	 Have CDC manage the process and data repository.
•	 Ensure that evidence database is open sourced.
•	 Involve stakeholder organizations using multi-tiered approach.
•	 Establish an official publication to disseminate information 
about best practices in laboratory medicine.
•	 Establish an overall coordinating/governing body with expert 
topic area panels.
•	 Finance the efforts with government sources.
•	 Use existing organizational structures, including an advisory body.
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These recommendations represent the conclusion of Phase I and the transition to Phase 
II in creating the Laboratory Medicine Best Practices recommendation process. As many 
other health organizations are at various stages of creating evidence-based best practices, 
guidelines, performance measures, and quality indicators, this initiative can benefit from 
their experiences. This effort is a large undertaking that will require sustained effort and 
collaboration. 
Next Steps
Consistent with the Laboratory Medicine Best Practices Workgroup’s recommendations, 
CDC is moving forward with Phase II, which involves the following key steps:
•	 Refine and develop process methods. 
•	 Develop a laboratory network for soliciting and creating practice evidence.
•	 Pilot test the process. 
•	 Evaluate alternative organizational structures for implementing the process. 
A key outcome of Phase II will be the additional refinement of the process, which will 
include the development of a new investigational component to fill the evidence gap in 
the literature. Work will again rely on the external Laboratory Medicine Best Practices 
Workgroup. Phase II will begin with the solicitation of professional and private sector groups 
interested in participating in a network to identify and evaluate candidate practices. This 
network will be fundamental in identifying potential studies, data sources, and participants to 
evaluate candidate practices in priority areas of laboratory practices or services. 
Pilot tests of at least three candidate practices in each of two topics (e.g., patient/specimen 
identification, critical values reporting, or reducing blood culture contamination) will be 
conducted. For each pilot test topic area, an expert panel will be convened whose primary 
function is to develop review protocols and complete evidence review for evaluating the 
candidate practices. The evaluation protocol will address guidance on evaluating both 
published and unpublished evidence of practice effectiveness. The result will be a refined 
evaluation process based on pilot-test findings. Evaluation of existing organizational models 
and structural components will provide a basis for making the Laboratory Medicine Best 
Practices evidence-based recommendation process operational.
CDC’s DLS is committed to fulfilling the recommendations of the IOM to “reduce burden of 
illness, injury, and disability and to improve the health and functioning of the people of the 
United States”3 in the field of laboratory medicine. The Laboratory Medicine Best Practices 
recommendation process provides an opportunity to identify and promote evidence-based 
practices that ultimately can lead to better health outcomes. 
Phase I set the groundwork for developing the process and revealed the need to develop 
a new approach—a more inclusive model that integrates traditional and nontraditional 
evidence. This process offers a broad based opportunity to systematically integrate and 
disseminate evidence by using explicit and transparent methods in a way that has not been 
done historically in the field of laboratory medicine. A primary focus of CDC’s efforts in 
Phase II and subsequently will be on ensuring that the recommendation process is sustainable 
and facilitates dissemination of best practices to relevant stakeholders. 
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APPENDIX C
Selection Process for Study Inclusion and Review Results
Patient/Specimen Identification
344 potentially relevant references 
identified
52 full articles retrieved for further 
review on the basis of inclusion criteria
17 articles for final data abstraction  
list (3 with multiple practices)
3 categories:
- Evidence (effectiveness)
- Feasibility Only 
- Related Information
13 studies with potential evidence of effectiveness 
8 Candidate Practices (first author[s], year)
1. Bar-coding ID systems: Bologna, 2002; Nichols, 2004; 
Turner, 2003
2. Dedicated Phlebotomy Services: Wagar, 2006
3. Education Program: Clark, 2001
4. Incident Reporting: Quillen, 2006 
5. Lock-out Practices: Mercurilali, 1994; Nichols, 2004
6. Marketing Campaign: Simpson, 2001
7. Zero Tolerance Policy: Dock, 2005; Simpson, 2001
8. Wristband Monitoring: Greenly, 2006; Zarbo, 2002
292 references excluded on the basis of
•	Screening of title/abstract 
•	Duplicate article  
38 articles excluded because
•	Practice not sufficiently described 
•	Did not assess practice/background/guideline 
•	Commentary/opinion 
6 additional articles identified by updated 
search 
•	3 excluded on the basis of inclusion criteria 






- For all multiple-choice options, check all responses that apply.
- Indicate the page or table number from the article where data are located to aid in 
checking the information.
I. Classification Information
1. Reviewer Name _________________________________________________________________
1.1 Review Completion Date  _________________________________________________
2. Topic: Patient/specimen identification errors
2.1 Subtopic _______________________________________________________________
2.2 Practice ________________________________________________________________ 
3. Citation (author[s], title of article, and publication date)  _________________________________
________________________________________________________________________________
4. Author(s) Affiliation _____________________________________________________________
5. Study Funding 
❏ Not performed or studied by a manufacturer 
❏ Supported by a manufacturer
❏	Performed by a manufacturer  
❏ Other, specify __________________________________________________________________
6. Reference Type
❏	Published article  ❏ Technical report   ❏ Presentation 
❏	Book/book chapter   ❏ Professional guidelines  ❏ Conference proceeding
❏	Other, specify  ___________________________________________________________
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